抽象的
在阻塞性气道疾病患者中,支气管扩张剂和支气管收缩剂的反应被认为是生理上相反的。在评估严重气道阻塞的病例中,激发挑战已被支气管扩张剂试验所取代。本研究的目的是研究普通人群中支气管收缩剂和支气管扩张剂的反应性及其互换性之间的关系。在Vlagtwedde-Vlaardingen的随访研究中,101名成年人被招募(平均年龄(SD)为55岁(11),其中男性67人,女性34人,吸烟者31人)。所有人都完成了一份关于呼吸道症状的问卷调查。分别使用组胺和特布他林,用累积剂量-反应曲线评估支气管收缩剂和支气管扩张剂的反应性。因此,这可能与气道的组胺敏感性有关(组胺浓度,一秒钟用力呼气量(FEV1)下降10% (PC10))至最大支气管扩张剂反应(delta FEV1)和对支气管扩张剂的敏感性(吸入特布他林的累积剂量,FEV1增加10% (RD10))。受试者有支气管收缩反应(PC10 <或= 16 mg x mL(-1);38例)的呼吸系统症状多于无症状者(63例)(40例对21%),基线FEV1值也较低(90例对预测的96%),但对支气管扩张剂的反应性相当。 Subjects with a bronchodilator response (delta FEV1 > or = 9% of the predicted value; n=13) did not differ from those without (n=88) for all parameters, including symptoms, allergy and pulmonary function. In those with a bronchoconstrictor response, there was a weak but significant correlation between the PC10 and RD10 (rho=-0.32), but not between PC10 and delta FEV1. This study suggests that bronchoconstrictor and bronchodilator responsiveness are not highly correlated, even in subjects with airways obstruction. Symptoms were associated with the presence of a bronchoconstrictor, but not a bronchodilator, response. We conclude that bronchoconstrictor and bronchodilator responsiveness are two different phenotypic markers that are not interchangeable in epidemiological studies.